Academic institutions grant commercial license for CRISPR-based SHERLOCK diagnostic tech
A group of academic institutions has granted a license for SHERLOCK™, the highly-sensitive, low-cost CRISPR-based diagnostic, for commercial uses in the developed world, while reserving rights to enable its broad use by organizations to serve developing nations as well as unmet public health needs in the developed world.
First unveiled in 2017, SHERLOCK lifts a barrier to rapid deployment of diagnostics in outbreak zones. The system (which stands for Specific High-sensitivity Enzymatic Reporter unLOCKing), allows clinicians to quickly and inexpensively diagnose disease and track epidemics, such as Ebola and Zika, without the need for extensive specialized equipment. SHERLOCK can detect the presence of viruses with an unmatched degree of sensitivity in clinical samples like blood or saliva.